ArticleBiology direct2026
Transcutaneous auricular vagus nerve stimulation alleviates chronic heart failure by targeting cathepsin K/p53-mediated ferroptosis.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHeart failure remains a major global health challenge, with ferroptosis implicated in its pathogenesis. Transcutaneous auricular vagus nerve stimulation (taVNS) has shown therapeutic potential for heart failure, but its regulatory mechanism underlying myocardial ferroptosis remains unclear.
methodsIsoproterenol-induced chronic heart failure (CHF) rats received taVNS for 2 weeks. Cardiac function was assessed by echocardiography, while myocardial pathology was analyzed using histological staining. Ferroptosis was evaluated via flow cytometry, transmission electron microscopy, and detection of ferroptosis markers. In vitro, Ang II-stimulated H9C2 cells were treated with Ach or subjected to cathepsin K knockdown.
resultsThe taVNS treatment improved LVEF and reduced LVIDd/LVIDs in CHF rats, accompanied by attenuated hypertrophy and fibrosis as well as decreased NT-proBNP, TNF-α, and IL-6 levels. Additionally, taVNS suppressed ferroptosis in cardiac tissues of CHF rats, as evidenced by reduced ROS and Fe²⁺ levels, decreased iron deposition, and upregulated SLC7A11 and GPX4 expression. However, the mAChR and α7-nAChR antagonists (atropine and MLA) abolished these benefits of taVNS. Moreover, taVNS inhibited cathepsin K/p53 pathway to suppress ferroptosis in CHF rat cardiac tissues, rescuing SLC7A11 and GPX4 expression and reducing ROS and Fe²⁺ levels. Acetylcholine replicated taVNS effects in vitro, reversing Erastin-induced ferroptosis and suppressing cathepsin K/p53 pathway.
conclusionThe taVNS treatment modulated cholinergic receptor activation to suppress cathepsin K/p53-mediated ferroptosis, ameliorating cardiac dysfunction in CHF. These findings revealed the specific mechanism by which taVNS exerted cardioprotection via cholinergic receptors, offering a novel therapeutic strategy for CHF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.